semaglutide allen 442: GLP-1 | A Closer Look At I’ve been incorporating GLP-1 medications

aHR: 0.73, 95% CI: 0.660.80) and in the GLP-1 RAs users group (Table 2, Table S5-6), supporting the association between GLP-1 RAs use and improved outcomes in type 2 diabetes patients with AKD (Fig

Family history of medullary thyroid carcinoma

It is not a sign the drug stopped working

Naturally, additional sessions are needed to see a discernible change

Global regulatory frameworksespecially the ICH S1 series guidelinesrequire structured carcinogenicity assessment: ICH S1A/S1B/S1C define when lifetime rodent studies are required Emphasis on hazard identification rather than direct human prediction Adoption of Weight-of-Evidence (WoE) approaches in ICH S1B(R1) The updated S1B(R1) guideline specifically encourages: Integration of mechanistic, exposure, and translational data Reduced reliance on 2-year rodent bioassays when justified Greater emphasis on human relevance and multi-factor evidence This shift reflects a broader regulatory evolution toward mechanism-based safety assessment rather than purely animal-driven hazard signals

[38] Medved, I., Brown, M.J., Bjorksten, A.R., Murphy, K.T., Petersen, A.C., Sostaric, S